(Press-News.org) The National Foundation for Cancer Research (NFCR) proudly announces the promotion of Brian Wachtel to Chief Development Officer. Brian will continue his responsibilities as the Executive Director, and his expanded role will further enhance his leadership within the organization.
Brian joined the National Foundation for Cancer Research in September 2016 as the Director of Corporate Partnerships & Special Events. In that capacity, he was in charge of organizing and expanding NFCR’s community outreach events. One of his important responsibilities was to launch third-party fundraising partnerships and youth-driven mentorship activities through NFCR’s signature programs, such as Play4TheCure, Youth Ambassador, and Arts4ThCure. Brian has gained respect from communities and expanded the community fundraising events significantly.
In May 2018, Brian was promoted to Senior Director of Corporate Partnerships & Special Events, where he continued to build on his previous success and demonstrated an innovative approach and strong initiatives to lead various community fundraising events. He also gained more knowledge and brought several significant new opportunities to NFCR.
The leadership recognized his efforts and dedication, and he was promoted to Executive Director in January 2019. In this capacity, Brian oversaw many NFCR donation-generating programs, from direct mail to digital marketing, events, major gifts, sponsorship development, and foundation relations.
“I couldn’t be more proud of Brian! I am thrilled to see him take on this expanded role,” said Dr. Sujuan Ba, President and CEO of NFCR. “His comprehensive understanding of NFCR’s mission and strategic vision has driven the organization’s growth and success. Brian’s journey at NFCR into a position of executive leadership is a prime example of the culture we promote at the foundation. Through hard work and commitment, all have an opportunity to grow and expand in their areas of impact. Brian has the trust of NFCR leadership and staff, as well as our supporters and donors, and I have no doubt he will continue to make further impact at NFCR and our mission. I look forward to seeing his continued impact as Chief Development Officer.”
“I am honored and excited to take on this expanded role at NFCR,” said Brian Wachtel. “During my tenure at NFCR, I have witnessed the advancements and development of the critically needed therapies and technologies among our scientists to help cancer patients. Having been touched personally by losing family members to this awful disease, I want to see a future without cancer. I am very committed and will work tirelessly to lead our fundraising efforts, generating the critically needed funding to support the innovative scientists making progress in the fight against cancer.”
About NFCR:
The National Foundation for Cancer Research (NFCR) is a 501(c)(3) nonprofit organization co-founded in 1973 by Nobel Laureate Dr. Albert Szent-Györgyi and Attorney/Business Entrepreneur Franklin Salisbury, Sr. NFCR provides scientists in the lab with the critical seed funding they need to make game-changing discoveries in cancer detection, treatments, prevention, and ultimately, a cure for all cancers. NFCR has distinguished itself in the cancer research sector by emphasizing “high-risk, high-impact” long-term and transformative pioneering research fields often overlooked by other major funding sources. With the support of more than 5.3 million individual donors over the last 51 years, NFCR has provided $415 million in funding to cancer research, prevention, and public education. NFCR-supported research has led to some of the most significant life-saving discoveries that benefit patients today. For more information, please visit www.nfcr.org.
END
Brian Wachtel is promoted to Chief Development Officer at NFCR
2024-07-09
ELSE PRESS RELEASES FROM THIS DATE:
Digital self-harm surges among U.S. teens from 2016 to 2021
2024-07-09
Adolescents worldwide have embraced social media and online platforms for self-expression and to explore their identity. This freedom, however, can lead to risky behaviors, especially with limited adult supervision. For example, digital self-harm is a recent, emerging trend where individuals anonymously post or share hurtful content about themselves online. This behavior can be mistaken for mistreatment by others, yet the perpetrator and victim are the same person.
First identified in 2010, digital self-harm has not received the same amount of scholarly scrutiny as other forms of self-directed abuse and has not been widely addressed by adults ...
UTSA joins new consortium dedicated to nuclear security and nonproliferation
2024-07-09
The University of Texas at San Antonio (UTSA) has joined one of two newly established university consortia committed to nuclear security and nonproliferation. The consortia were awarded $50 million in cooperative agreements by the Office of Defense Nuclear Nonproliferation in the U.S. Department of Energy’s National Nuclear Security Administration (DOE NNSA).
“The pressing challenges of nuclear security and nonproliferation require a concerted effort from experts across the country,” said JoAnn Browning, UTSA interim vice president for research. ...
Diabetes increases the risk of failure in spinal fusion procedures
2024-07-09
A new study from orthopaedic researchers at The University of Toledo has found lumbar spinal fusion procedures are far more likely to fail in individuals with diabetes.
“We’ve known for a long time that diabetic patients are at high risk of infection from any surgery, including spinal fusion,” said Dr. Hossein Elgafy, a professor of orthopaedics in the College of Medicine and Life Sciences and chief of spine surgery at UTMC. “More recently, however, physicians have taken a closer look at the high ...
Brain-computer interface therapy for stroke survivors
2024-07-09
A personalized brain-computer interface therapy, RehabSwift, significantly enhances hand mobility for stroke survivors. Strokes often lead to impaired hand function, presenting substantial challenges in daily activities. Sam Darvishi and colleagues developed and tested a brain-computer interface therapy that translates imagined hand movements into real actions using a personalized algorithm and bionic hands. The study involved twelve chronic stroke survivors from South Australia who had limited use of their arms but retained clear thinking abilities. Throughout 18 sessions, participants used the RehabSwift system, which included a special cap that ...
SynGAP Research Fund (SRF) increases support for SYNGAP1 organoid research at the University of Southern California’s Quadrato Lab
2024-07-09
MILL VALLEY, Calif. – July 9, 2024 – SynGAP Research Fund (SRF), a 501(c)(3) public charity whose mission is to improve the quality of life for patients suffering from SYNGAP1-Related Disorders (SRD) through the research and development of treatments, therapies, and support systems, has awarded a $130,000 grant to the University of Southern California’s Quadrato Lab to inspect and stratify the effects of specific SYNGAP1 variants on their patient-derived neuronal model system, furthering the world’s understanding ...
Study finds 1 in 12 patients labeled as having ‘benign’ results actually had high-risk prostate cancer
2024-07-09
New research highlights the challenge of balancing the risks of overdiagnosing and underdiagnosing prostate cancer early enough to intervene and minimize risk of death. Recently, some experts have called for the lowest grade of prostate cancer—biopsy Gleason Grade Group (GGG) 1—to be reclassified as ‘benign.’ But a new study led by a researcher from Mass General Brigham has found that many patients with a biopsy GGG1 may have a more aggressive cancer than their biopsy alone suggests.
By looking at data from more than 10,000 patients at a university in Germany, researchers found that at least 8 percent of patients with this ...
Marcos Vilela wins Lilly Research Award for Doctoral Students
2024-07-09
The Royal Spanish Society of Chemistry (RSEQ) and Lilly have announced the winning theses of the 22nd Research Awards for Doctoral Students, which acknowledge outstanding work in the fields of Organic, Pharmaceutical, and Analytical Chemistry. Marcos Vilela, currently pursuing his PhD at the Center for Research in Biological Chemistry and Molecular Materials (CiQUS) at the University of Santiago de Compostela (USC), was awarded alongside Andrea Palone from the University of Girona (UdG) and the University of Rome "Tor Vergata," and Beatriz Arévalo from the Complutense University of Madrid (UCM).
Marcos' thesis, supervised by CiQUS Principal ...
Trust, more than knowledge, critical for acceptance of fully autonomous vehicles
2024-07-09
PULLMAN, Wash. – While not yet on the market, fully autonomous vehicles are promoted as a way to make road travel dramatically safer, but a recent study found that knowing more about them did not improve people’s perception of their risk. They needed to have more trust in them too.
This study adds to the evidence from other research that knowledge alone is not enough to sway people’s attitudes toward complex technology and science, such as gene editing or climate change. In this case, Washington State University researchers found that trust in the autonomous vehicles’ reliability and performance played the strongest role in improving ...
Run screaming or slow retreat? New study advances understanding of brain responses to emotionally-charged scenes
2024-07-09
The ability to recognise and respond to emotionally-charged situations is essential to a species’ evolutionary success. A new study published today [July 9th] in Nature Communications advances our understanding of how the brain responds to emotionally charged objects and scenes.
The research, led by Trinity College Dublin neuroscientist Prof. Sonia Bishop and Google researcher Samy Abdel-Ghaffar while he was a PhD student in Prof. Bishop's lab at UC Berkeley, has identified how the brain represents different categories of emotional stimuli in a way that allows for ...
Brain neurotransmitter receptor antagonist found to prevent opioid addiction in mice
2024-07-09
New research led by UCLA Health has found a drug that treats insomnia works to prevent the addictive effects of the morphine opioids in mice while still providing effective pain relief.
The study, published in the journal Nature Mental Health, concluded that suvorexant, which blocks brain receptors for a neurotransmitter called hypocretin, prevents opioid addiction. At high doses in humans, suvorexant induces sleep and is used to treat insomnia. But sleep was not induced, and behavioral alertness was maintained, at the much lower doses effective in preventing ...